Lanreotide

Fat LossFDA-approved somatostatin analogEstablished

Lanreotide is an FDA-approved somatostatin analog. Lanreotide is a cyclic octapeptide analog of somatostatin with high affinity for somatostatin receptor subtypes 2 and 5. Receptor activation inhibits growth hormone release from the pituitary and suppresses secretion of several gut hormones, and in neuroendocrine tumours also exerts direct antiproliferative effects.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): 1096.3 g/mol
Half-life: —
FDA status: Approved
Evidence level: FDA Approved
Human dose established: Yes
Administration Route: Subcutaneous
Frequency: Every 4 weeks
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026

Research summary

Long-acting somatostatin analog approved for acromegaly, for unresectable gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.

Research evidence

Regulatory review (FDA label)3 reviewed sources
Controlled human trialsNone in reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Lanreotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Lanreotide dosage evidence

Lanreotide has FDA-approved human dosages. Somatuline Depot for acromegaly starts at 90 mg by deep injection under the skin every 4 weeks for 3 months, then is adjusted to 60, 90 or 120 mg. For gastroenteropancreatic neuroendocrine tumors and for carcinoid syndrome it is 120 mg every 4 weeks.

FDA Approved

Dosage evidence summary for Lanreotide
Human dosing established	Yes
Studied dose range	60–120 mg every 4 weeks, by indication
Route	Subcutaneous
Frequency	Every 4 weeks
Duration studied	Long-term
Titration	Acromegaly: 90 mg for 3 months, then 90 mg kept, raised to 120 mg or lowered to 60 mg by GH, IGF-1 and symptoms. 60 mg to start with moderate or severe kidney or liver impairment.
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Lanreotide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Somatuline Depot, acromegalyFDA-approved label · FDA prescribing information	Adults with acromegaly with an inadequate response to, or who cannot have, surgery or radiotherapy	Start 90 mg for 3 months; then 60, 90 or 120 mg by GH, IGF-1 and symptoms. Start 60 mg with moderate or severe renal or hepatic impairment	Deep subcutaneous, prefilled syringe	Every 4 weeks	Long-term	GH and IGF-1 control	SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed
FDA label — Somatuline Depot, GEP-NETsFDA-approved label · FDA prescribing information	Adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors	120 mg	Deep subcutaneous	Every 4 weeks	Long-term	Improved progression-free survival	SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed
FDA label — Somatuline Depot, carcinoid syndromeFDA-approved label · FDA prescribing information	Adults with carcinoid syndrome	120 mg (no extra dose if already treated for GEP-NETs)	Deep subcutaneous	Every 4 weeks	Long-term	Less use of short-acting somatostatin analog rescue therapy	SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed

Where sources disagree

Generic lanreotide injections from other labellers are also listed on DailyMed; the doses here are from the originator Somatuline Depot label.
The label warns about gallstones, high or low blood sugar, slower heart rate and reduced thyroid function.

Lanreotide dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Lanreotide
Molecular formula	C54H69N11O10S2
Molecular weight	1096.3 g/mol
PubChem CID	6918011
FDA UNII	0G3DE8943Y
ChEMBL	CHEMBL1201185

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Lanreotide is a cyclic octapeptide analog of somatostatin with high affinity for somatostatin receptor subtypes 2 and 5. Receptor activation inhibits growth hormone release from the pituitary and suppresses secretion of several gut hormones, and in neuroendocrine tumours also exerts direct antiproliferative effects. Its supersaturated aqueous depot formulation forms a subcutaneous reservoir that releases drug over several weeks.

Studies

Research statistics

1,278 PubMed publications · 56.0% human clinical research · 84 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Lanreotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Lanreotide
FDA status	Approved
Research status	Approved product (see FDA status)
Availability	Prescription-Only
WADA (sport)	Unknown / Not Listed
Library classification	FDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

—

Lanreotide side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Lanreotide: frequently asked questions

What is Lanreotide?

Long-acting somatostatin analog approved for acromegaly, for unresectable gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.

How does Lanreotide work?

Is Lanreotide FDA approved?

Yes. Lanreotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What peptides are similar to Lanreotide?

Compounds most often compared with Lanreotide include Octreotide, Pasireotide, Human Growth Hormone (Somatropin) and Lonapegsomatropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Lanreotide in metastatic enteropancreatic neuroendocrine tumors — N Engl J Med, 2014
External reference
The safety of lanreotide for neuroendocrine tumor — Expert Opin Drug Saf, 2019
External reference
Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors — Expert Opin Pharmacother, 2016
External reference
Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors — Curr Oncol Rep, 2016
External reference
Lanreotide autogel in acromegaly - a decade on — Expert Opin Pharmacother, 2014
External reference

Related research, comparisons & guides

Related peptides

Human Growth Hormone (Somatropin)

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Lanreotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Lanreotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →